The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis

Autoimmunity Reviews

Volumn 9, Issue 1, 2009, Pages 53-57

  van Leeuwen, M ^a   Damoiseaux, J ^a   Duijvestijn, A ^a   Tervaert, J W Cohen ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Anti oxLDL antibodies; Atherosclerosis; B cell; Passive immunization; Therapy

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY;

ADAPTIVE IMMUNITY; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL FUNCTION; DRUG EFFECT; HUMAN; LIPID OXIDATION; NONHUMAN; REVIEW;

ANIMALS; ANTIBODIES; ATHEROSCLEROSIS; B-LYMPHOCYTES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; LIPOPROTEINS, LDL; LYMPHOCYTE DEPLETION; MICE; RECEPTORS, IGG;

EID: 69649089891     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.03.001     Document Type: Review

References (40)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 16 (2005) 1685-1695
2. Nilsson J., and Hansson G.K. Autoimmunity in atherosclerosis: a protective response losing control?. J Intern Med 263 5 (2008) 464-478
3. Zampieri S., Iaccarino L., Ghirardello A., Tarricone E., Arienti S., Sarzi-Puttini P., et al. Systemic lupus erythematosus, atherosclerosis, and autoantibodies. Ann N Y Acad Sci 1051 (2005) 351-361
4. Gounopoulos P., Merki E., Hansen L.F., Choi S.H., and Tsimikas S. Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease. Minerva Cardioangiol 55 6 (2007) 821-837
5. Yanaba K., Bouaziz J.D., Matsushita T., Magro C.M., St Clair E.W., and Tedder T.F. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 223 (2008) 284-299
6. Binder C.J., and Silverman G.J. Natural antibodies and the autoimmunity of atherosclerosis. Springer Semin Immunopathol 26 4 (2005) 385-404
7. Bouaziz J.D., Yanaba K., and Tedder T.F. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 224 (2008) 201-214
8. van der Wal A.C., Das P.K., Bentz van de Berg D., van der Loos C.M., and Becker A.E. Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response. . Lab Invest 61 2 (1989) 166-170
9. Yla-Herttuala S., Palinski W., Butler S.W., Picard S., Steinberg D., and Witztum J.L. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 14 1 (1994) 32-40
10. Houtkamp M.A., de Boer O.J., van der Loos C.M., van der Wal A.C., and Becker A.E. Adventitial infiltrates associated with advanced atherosclerotic plaques: structural organization suggests generation of local humoral immune responses. J Pathol 193 2 (2001) 263-269
11. Zhou X., and Hansson G.K. Detection of B cells and proinflammatory cytokines in atherosclerotic plaques of hypercholesterolaemic apolipoprotein E knockout mice. Scand J Immunol 50 1 (1999) 25-30
12. Caligiuri G., Nicoletti A., Poirier B., and Hansson G.K. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 109 6 (2002) 745-753
13. Major A.S., Fazio S., and Linton M.F. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 22 11 (2002) 1892-1898
14. Matsuura E., Hughes G.R., and Khamashta M.A. Oxidation of LDL and its clinical implication. Autoimmun Rev 7 7 (2008) 558-566
15. Salonen J.T., Yla-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339 8798 (1992) 883-887
16. Palinski W., Tangirala R.K., Miller E., Young S.G., and Witztum J.L. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol 15 10 (1995) 1569-1576
17. Shaw P.X., Horkko S., Chang M.K., Curtiss L.K., Palinski W., Silverman G.J., et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 105 12 (2000) 1731-1740
18. Binder C.J., Hartvigsen K., Chang M.K., Miller M., Broide D., Palinski W., et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 114 3 (2004) 427-437
19. Binder C.J., Horkko S., Dewan A., Chang M.K., Kieu E.P., Goodyear C.S., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 9 6 (2003) 736-743
20. Faria-Neto J.R., Chyu K.Y., Li X., Dimayuga P.C., Ferreira C., Yano J., et al. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 189 1 (2006) 83-90
21. Lewis M.J., Malik T.H., Ehrenstein M.R., Boyle J.J., Botto M., and Haskard D.O. Hierarchical contributions of IgM and complement C1q in protection against murine atherosclerosis (Abstract). FASEB Journal 22 (2008) 463.2
22. Hulthe J., Bokemark L., and Fagerberg B. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 21 1 (2001) 101-107
23. Karvonen J., Paivansalo M., Kesaniemi Y.A., and Horkko S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108 17 (2003) 2107-2112
24. Tsimikas S., Brilakis E.S., Lennon R.J., Miller E.R., Witztum J.L., McConnell J.P., et al. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res 48 2 (2007) 425-433
25. Goncalves I., Gronholdt M.L., Soderberg I., Ares M.P., Nordestgaard B.G., Bentzon J.F., et al. Humoral immune response against defined oxidized low-density lipoprotein antigens reflects structure and disease activity of carotid plaques. Arterioscler Thromb Vasc Biol 25 6 (2005) 1250-1255
26. Sjoberg B.G., Su J., Dahlbom I., Gronlund H., Wikstrom M., Hedblad B., et al. Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. Atherosclerosis (2008)
27. Sampi M., Ukkola O., Paivansalo M., Kesaniemi Y.A., Binder C.J., and Horkko S. Plasma interleukin-5 levels are related to antibodies binding to oxidized low-density lipoprotein and to decreased subclinical atherosclerosis. J Am Coll Cardiol 52 17 (2008) 1370-1378
28. Shoenfeld Y., Wu R., Dearing L.D., and Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective?. Circulation 110 17 (2004) 2552-2558
29. Huang Y., Fleming A.J., Wu S., Virella G., and Lopes-Virella M.F. Fc-gamma receptor cross-linking by immune complexes induces matrix metalloproteinase-1 in U937 cells via mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol 20 12 (2000) 2533-2538
30. Tedder T.F., Baras A., and Xiu Y. Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol 28 4 (2006) 351-364
31. Nicoletti A., Kaveri S., Caligiuri G., Bariety J., and Hansson G.K. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 102 5 (1998) 910-918
32. Udi N., and Yehuda S. Intravenous immunoglobulin - indications and mechanisms in cardiovascular diseases. Autoimmun Rev 7 6 (2008) 445-452
33. Schiopu A., Bengtsson J., Soderberg I., Janciauskiene S., Lindgren S., Ares M.P., et al. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 110 14 (2004) 2047-2052
34. Strom A., Fredrikson G.N., Schiopu A., Ljungcrantz I., Soderberg I., Jansson B., et al. Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100. Atherosclerosis 190 2 (2007) 298-305
35. Hernandez-Vargas P., Ortiz-Munoz G., Lopez-Franco O., Suzuki Y., Gallego-Delgado J., Sanjuan G., et al. Fcgamma receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice. Circ Res 99 11 (2006) 1188-1196
36. Shaw P.X., Horkko S., Tsimikas S., Chang M.K., Palinski W., Silverman G.J., et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 21 8 (2001) 1333-1339
37. Damoiseaux J., Rijkers G., and Tervaert J.W. Pneumococcal vaccination does not increase circulating levels of IgM antibodies to oxidized LDL in humans and therefore precludes an anti-atherogenic effect. Atherosclerosis 190 1 (2007) 10-11
38. Lamontagne F., Garant M.P., Carvalho J.C., Lanthier L., Smieja M., and Pilon D. Pneumococcal vaccination and risk of myocardial infarction. Cmaj 179 8 (2008) 773-777
39. Musher D.M., Rueda A.M., Kaka A.S., and Mapara S.M. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 45 2 (2007) 158-165
40. van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martinez-Martinez P., Vermeulen E., et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317 5844 (2007) 1554-1557